Botox or Sacral Stimulation: Four ROSETTA Trial Checks

A treatment comparison is easier to use when you can put its numbers beside the procedure you have been offered. Before choosing bladder Botox or an implanted sacral stimulator, take these four checks to your specialist.

Check the population and dose

ROSETTA studied women with persistent urgency leaks after behavioral treatment and two medicines. Of 386 randomized, 364 contributed to the primary analysis. Participants knew their treatment. NIH funded the study.¹

The trial used 200 units of onabotulinumtoxinA.¹

The current US BOTOX label specifies 100 units for overactive bladder; its 200-unit adult bladder dose is for detrusor overactivity associated with a neurologic condition.² NICE³ guidance for England also starts overactive-bladder injections at 100 units, with higher subsequent doses considered in specified circumstances.³

Ask which dose your clinician proposes and why. If the answer is 100 units, ask for evidence matching that dose when discussing likely benefit and catheter use.

Check what the leak count measures

Across six months, daily urgency leaks fell by 3.9 with Botox versus 3.3 with stimulation: a difference of 0.63 episodes, 95% confidence interval 0.13 to 1.14. Clinical importance was uncertain.¹

Those figures describe an average change in episode counts. Ask the specialist to describe your own target in the same terms: fewer leaks during work, fewer clothing changes, or another outcome you can record. Write down how you will judge benefit and when the clinic will review it.

Check the catheter figure’s timeframe

At least one treated urinary infection occurred in 35% versus 11%, respectively. In the Botox arm, 38/191 (20%) met catheterization criteria at some point through six months.¹

The US label requires willingness and ability to start catheterization if necessary. For people not already catheterizing, it calls for a bladder-emptying check within two weeks, then periodically as appropriate through twelve weeks. Active urinary infection prevents bladder injection.²

Before booking, establish who teaches catheter use, supplies the equipment and answers problems afterward. Our bladder Botox follow-up guide has questions for making those arrangements.

Check who entered the longer analysis

Two-year efficacy analyses concerned initial responders; 260/298 had outcome data. Repeat injections were allowed. No statistically significant between-group difference in average leak reduction was found.⁴

Ask how the clinic would manage an inadequate first response, a benefit that fades, or difficulty attending repeat visits.

For sacral stimulation, NICE³ asks clinicians to discuss test stimulation, possible failure, the long-term commitment, adverse effects and possible surgical revision.³ Our nerve-stimulation comparison explains how the implanted approach differs from ankle-based treatment.

Leave with the practical plan

Request the proposed dose or device, review date and contact number in writing. Have the team explain what happens if the first treatment does not meet your agreed goal.

Laugh, Sneeze, Jump covers specialist options for urgency leaks and includes “What to Say in the Room,” with a three-day bladder record and questions about benefit, timing and risks. Use that section to prepare your comparison appointment. See the book.

The BOTOX boxed warning covers toxin effects spreading beyond the injection site. Seek immediate medical help for problems swallowing, speaking or breathing after treatment.²